MacroGenics, Inc. (NASDAQ:MGNX) has analysts on the Bullish side this week.

Investors sentiment decreased to 0.92 in Q2 2019. Its down 1.23, from 2.15 in 2019Q1. It fall, as 28 investors sold MacroGenics, Inc. shares while 34 reduced holdings. 12 funds opened positions while 45 raised stakes. 39.29 million shares or 2.04% less from 40.11 million shares in 2019Q1 were reported.
32,771 are held by Barclays Pcl. Grp holds 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX) for 30,308 shares. Legal General Grp Public Ltd Company holds 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX) for 9,059 shares. Great West Life Assurance Can stated it has 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Moreover, California State Teachers Retirement System has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX). Alliancebernstein L P invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Clearbridge Lc has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Bnp Paribas Arbitrage invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Royal State Bank Of Canada accumulated 498 shares. Wasatch Inc invested in 0.24% or 1.42 million shares. Stifel Fin Corporation owns 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 19,337 shares. Ameritas Investment Partners Incorporated stated it has 4,075 shares. Goldman Sachs Grp Inc has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Gmt Capital Corp stated it has 1.05 million shares. Parametric Port Assocs Ltd Liability holds 38,011 shares or 0% of its portfolio.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 2 analysts covering Macrogenics (NASDAQ:MGNX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Macrogenics has $29 highest and $2500 lowest target. $27’s average target is 137.26% above currents $11.38 stock price. Macrogenics had 3 analyst reports since April 17, 2019 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Thursday, August 1. Below is a list of MacroGenics, Inc. (NASDAQ:MGNX) latest ratings and price target changes.

01/08/2019 Broker: Stifel Nicolaus Rating: Buy Old Target: $29.0000 New Target: $25.0000 Maintain
03/05/2019 Broker: Inc. – Common Stock Rating: Wedbush 26.0000
17/04/2019 Broker: Credit Suisse Rating: Outperform New Target: $29 Initiates Coverage On

The stock increased 0.53% or $0.06 during the last trading session, reaching $11.38. About 300,947 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has declined 28.01% since October 12, 2018 and is downtrending. It has underperformed by 28.01% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $556.41 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

More notable recent MacroGenics, Inc. (NASDAQ:MGNX) news were published by: Globenewswire.com which released: “Zhang Investor Law Announces Securities Class Action Lawsuit MacroGenics, Inc.- MGNX – GlobeNewswire” on October 03, 2019, also Fool.com with their article: “3 Stocks With Big News Coming at ASCO 2019 – Motley Fool” published on May 15, 2019, Globenewswire.com published: “MacroGenics to Participate in Upcoming Investor Conferences – GlobeNewswire” on August 29, 2019. More interesting news about MacroGenics, Inc. (NASDAQ:MGNX) were released by: Finance.Yahoo.com and their article: “INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm – Yahoo Finance” published on September 24, 2019 as well as Globenewswire.com‘s news article titled: “MacroGenics Provides Update on Corporate Progress and 3rd Quarter 2018 Financial Results – GlobeNewswire” with publication date: November 07, 2018.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.